232 results for "appropriation"
The long roots of ibogaine: A journey from plant to pharmaceutical
Journal of Psychedelic Studies – March 09, 2026
Summary
Ibogaine's history reveals a complex interplay of colonialism and cultural appropriation, with significant implications for its role in modern medicine. Prior to the 1960s, ibogaine was commercialized in various products, including Dragées Nyrdahl and Ibobiose, highlighting its international diffusion. Notably, it was first used for substance use disorder treatment in Mexico in 1913, challenging dominant narratives. The analysis underscores the importance of indigenous knowledge in shaping scientific understanding, emphasizing the need to recognize the contributions of the Congo Basin communities in ibogaine's development and commercialization.
Abstract
Abstract Background and aims Ibogaine, one of the oldest psychedelic alkaloids introduced to Western society and medicine, has a largely overlooked...
We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐ N , N ‐Dimethyltryptamine
ChemMedChem – February 25, 2026
Summary
Bufotenin and its derivative, 5-MeO-DMT, are powerful psychedelics with potential in treating psychological disorders and neurodegenerative diseases. Despite being used in traditional medicine, their research has been hindered by prohibition. However, the recent trend toward legalization has spurred interest, leading to an increase in clinical studies. This review compiles all known academic and patent syntheses of bufotenin as of fall 2024, offering researchers valuable insights into efficient production methods while addressing challenges for commercial-scale availability.
Abstract
Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are ...
SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
OpenAlex – February 24, 2026
Summary
Psilocybin and MDMA, alongside traditional SSRIs, show promise as effective treatments for Post-Traumatic Stress Disorder (PTSD) by modulating serotonin-related neural circuits. With a focus on their biological mechanisms, this position paper emphasizes the need for a deeper understanding of these substances at molecular and neural levels. The exploration of their therapeutic potential could lead to innovative treatment modalities for the 7-8% of the population affected by PTSD. A multidisciplinary approach is essential for developing effective therapies that address complex PTSD symptoms.
Abstract
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methyl...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.
CNS drugs – January 17, 2026
Summary
Combining MAOIs with certain psychoactive substances can be fatal. A comprehensive review of 219 publications, including 20 randomized trials and 56 case reports, found MAOIs combined with amphetamines, MDMA, or some opioids pose serious risks, including serotonin toxicity and hypertensive crises. Fatalities were reported with eight different substances. However, MAOI treatment can be carefully managed with substances like low-tyramine alcohol, cannabis, or caffeine under monitoring. Robust human data supporting MAOIs for treating substance use disorders are absent. Further safety investigation in these complex patients is crucial.
Abstract
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric condit...
La Ayahuasca como recurso educativo: integración de saberes ancestrales y educación contemporánea
Revista Científica Multidisciplinaria SAPIENTIAE – January 15, 2026
Summary
Ayahuasca, traditionally used by Indigenous peoples of the Amazon, serves as a powerful educational tool that enhances intercultural understanding. Involving 200 participants from diverse backgrounds, 85% reported improved cultural awareness and critical thinking when ayahuasca was integrated into learning processes. This sacred brew symbolizes Indigenous worldviews and helps bridge ancestral knowledge with modern education, fostering respect for environmental ethics and sustainability. By promoting dialogue between Indigenous and scientific perspectives, ayahuasca enriches education for both Indigenous and non-Indigenous communities, revitalizing traditions and encouraging plural knowledge systems.
Abstract
Ayahuasca, an ancestral beverage used by indigenous peoples of the Amazon, has transcended its ritual and medicinal use to become a significant res...
Mindfulness Components and Their Clinical Efficacy: A Critical Review of an Ongoing Debate.
Healthcare (Basel, Switzerland) – January 13, 2026
Summary
For lasting mental health benefits from mindfulness, cognitive and emotional regulation skills like acceptance appear more crucial than meditation alone. Mindfulness programs demonstrate moderate clinical efficacy in reducing anxiety, depression, and stress. However, reported effect sizes are often inflated due to methodological issues. While meditation is key, health education and informal practices also contribute significantly. When assessing its overall impact, mindfulness shows comparable benefits to established treatments like Cognitive Behavioral Therapy, but a balanced understanding is essential for appropriate integration into mental health care.
Abstract
The rapid expansion of mindfulness research has generated both enthusiasm and controversy regarding its actual clinical value. While meditation is ...
Mindfulness-Based Interventions to Implement the Psychological Well-Being of Nursing Students: A Scoping Review.
Healthcare (Basel, Switzerland) – January 04, 2026
Summary
Mindfulness practices significantly boost undergraduate nursing students' psychological well-being. A review of 55 articles, selected from 763, highlights mindfulness as a powerful tool for pre-licensure students. These interventions enhance empathy and self-efficacy, crucial for future patient care. While stress and anxiety are commonly addressed, integrating mindfulness can also build resilience and satisfaction. Future efforts should focus on standardized approaches to embed mindful self-compassion into nursing curricula, optimizing psychological well-being for all nursing students.
Abstract
Background/Objectives: Mindfulness is a meditative practice that increases levels of awareness and attention. Introducing this practice into the cu...
Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
Depersonalization-derealization disorder (DDD) can follow psychedelic use, affecting individuals for months. In a case series of three patients treated at an outpatient clinic, symptoms arose after exposure to LSD, psilocybin, or 5-methoxy-dimethyltryptamine. Misdiagnoses hindered timely treatment, highlighting the need for accurate assessment. Psychotherapy emerged as a primary intervention, proving beneficial in alleviating distress. By exploring acute experiences with psychedelics, therapists can enhance patient relationships and address psychodynamic factors, paving the way for more effective psychological interventions in clinical psychology and psychiatry.
Abstract
Abstract: Aims: Symptoms of depersonalization (DP) and derealization (DR) are commonly reported during the acute effects of classic psychedelics. I...
Novel approaches for drug development against chronic primary pain: A systematic review.
British journal of pharmacology – November 14, 2025
Summary
Millions suffer from chronic primary pain, yet traditional treatments often fall short. A comprehensive review of clinical trials aimed to identify novel and repurposed drug approaches for conditions like fibromyalgia, complex regional pain syndrome, and chronic low back pain. While a definitive breakthrough is still sought, promising candidates targeting cannabinoid, glutamate, GABAergic, neuroinflammatory, and immune mechanisms are emerging, demonstrating efficacy and safety. Notably, cannabidiol and ketamine show broad potential, having been tested for all three pain types. Focused drug development in these specific areas offers significant hope for improved pain management.
Abstract
Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
Journal of Humanistic Psychology – November 10, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) may offer therapeutic benefits, as evidenced by a randomized controlled trial involving 40 healthy males. Participants took 10 µg of LSD every third day for six weeks, leading to themes like improved mood, enhanced social interactions, and increased mindfulness. Notably, changes in anxiety levels highlighted the need for careful patient selection. Insights into set and setting, along with perceived bidirectionality of effects, suggest important considerations for future psychedelic clinical trials and their potential in treating mood disorders.
Abstract
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have ...
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs
Journal of Psychopharmacology – October 16, 2025
Summary
The rapid advancement in Psychedelics and Drug Studies presents significant regulatory hurdles for new drug candidates. Assessing abuse and dependence potential is crucial before rescheduling C-I controlled substances like psilocybin, N,N-dimethyltryptamine, and lysergic acid diethylamide. A proposed framework categorizes these, along with novel analogues and "grey area" psychedelics, outlining appropriate testing. This ensures proper evaluation of chemical synthesis and alkaloids for scheduling under acts like the US Controlled Substances Act, impacting Forensic Toxicology and Drug Analysis globally.
Abstract
Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators....
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study.
Journal of affective disorders – October 15, 2025
Summary
Ketamine injections offer new hope for patients with treatment-resistant depression, showing both clinical benefits and cost savings in healthcare settings. This groundbreaking analysis tracked 174 patients receiving either ketamine or a control medication over 8 weeks. Results revealed ketamine was more effective and less expensive than traditional treatments from a healthcare perspective, with significant improvements in quality of life.
Abstract
Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness...
Side Effects and Adverse Events in Prehospital Ketamine Analgesia for Trauma
International Journal of Paramedicine – October 08, 2025
Summary
Ketamine, an effective analgesic for traumatic pain, shows a low incidence of serious adverse effects in prehospital settings, with only 3% experiencing severe complications among 1,301 patients analyzed across eight studies. Reported side effects included cardiovascular, neuropsychological, and gastrointestinal issues, as well as airway compromise. Notably, variations in dosing and observation periods limit the generalizability of findings. When used judiciously in selected patients, Ketamine can enhance pain management strategies for paramedics, improving patient outcomes and quality of life.
Abstract
Introduction: In the United Kingdom, pain management is a frequent reason for ambulance use. The benefits of adequate pain management are well docu...
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness
Australian & New Zealand Journal of Psychiatry – September 20, 2025
Summary
Ketamine and esketamine show promise in alleviating depression symptoms for individuals with borderline personality disorder, potentially benefiting a population often grappling with severe mental health challenges. However, caution is warranted due to reports of suicidal ideation and self-harm post-treatment cessation. Limited data from existing studies highlight the risk of acute dissociation in these patients. While current findings are encouraging, a larger randomized controlled trial is essential to better understand efficacy and side effects before widespread clinical application.
Abstract
This is the first systematic review to assess the effectiveness of ketamine/esketamine in this cohort. Our findings suggest that ketamine/esketamin...
Reappraisal of the hype and hope offered by psilocybin treatment of depression
New Zealand Medical Journal – September 15, 2025
Summary
Early findings suggest psilocybin holds promise for depression, a significant area in Psychology and Mental Health. However, a review of Psychedelics and Drug Studies reveals methodological challenges like expectation bias. While generally well tolerated, side effects are often not systematically reported, and some recipients may experience harm. Comparing with ketamine for treatment-resistant depression shows similar issues, but ketamine's positive evidence is currently stronger. Therefore, the current data on psilocybin's efficacy and safety in Psychotherapy Techniques and Applications is insufficient to warrant wider availability for depression treatment.
Abstract
aim: To provide a balanced account of psilocybin treatment of depression for expectations to be appropriately set. method: Review and discussion of...
577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Australia's regulatory approval for psilocybin in treatment-resistant depression signals a major Psychiatry breakthrough. This psychedelic, central to Drug Studies, initiates specific Chemical Reactions by influencing brain serotonin receptors, a critical Neurotransmitter Receptor Influence on Behavior. Clinical psychology reveals psilocybin provides rapid, robust antidepressant effects, enduring for months to a year after only one or two treatment sessions. Neuroimaging further illuminates how this modulates brain circuits, offering deep insights into its therapeutic promise for mental health.
Abstract
Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials ...
Evaluation of Two Spectroscopic Techniques to Estimate the MDMA Dose of Ecstasy-Like Tablets, an On-Site Approach.
Drug testing and analysis – July 22, 2025
Summary
Rapidly assessing the MDMA dose in seized tablets offers a critical public safety advantage. Researchers investigated two portable spectroscopic techniques for this on-site, rapid dose estimation. Using 98 illicit tablets, these methods were rigorously compared against laboratory gold standards. Both near-infrared and Fourier-transform infrared spectroscopic tools reliably predicted the MDMA dose, proving highly effective for rapid on-site application. This capability significantly aids public health and law enforcement efforts.
Abstract
MDMA, commonly known as "ecstasy," is widely used in clubs and at festivals, earning its reputation as a "party drug." The increasing demand for ra...
Varying the High-pass-Cut Off Frequency Influences the Accuracy of the Model for Detection of Mind State Associated with Himalayan Yoga and Vipassana Meditation.
Annals of neurosciences – July 19, 2025
Summary
The use of a 1 Hz high-pass filter significantly enhances meditation classification accuracy, achieving 100% for Himalayan Yoga and 99.45% for Vipassana using a Convolutional Neural Network (CNN). In this analysis, two classification tasks were performed on electroencephalogram (EEG) data from meditation practices, with sample sizes indicating robust results. The Inception Convolutional Gated Recurrent Neural Network (IC-RNN) also showed impressive results, reaching 86.19% for Vipassana and 88.15% for Himalayan Yoga. These findings highlight the importance of pre-processing techniques in deep learning applications for mental state identification.
Abstract
Meditation and Yoga practices are being adopted and gaining considerable interest as a tool that prevents the occurrence of numerous ailments. Medi...
Developing a mindfulness program for pre-clinical medical students in Indonesia: a mixed-methods study on suitability and appropriateness.
BMC medical education – July 17, 2025
Summary
Medical students face significant psychological distress, with high rates of anxiety and burnout. A newly developed Mindfulness Program for Pre-Clinical Medical Students in Indonesia (MPPMS-I) shows promise in addressing these issues. In a study involving first-, second-, and third-year students, interest levels ranged from 5.75 to 6.6 out of 7, indicating strong engagement. Participants found the program highly relevant to their academic challenges and expressed a high likelihood of applying mindfulness techniques like S.T.O.P. meditation in daily life, highlighting its feasibility and cultural fit for improving student well-being.
Abstract
Medical students experience high rates of psychological distress, including depression, anxiety, burnout, and suicidality, due to rigorous academic...
[Hypnosis: An ancient therapeutic practice revived in modern science].
Psychiatrike = Psychiatriki – July 02, 2025
Summary
Brain scans reveal hypnosis creates a unique mental state, distinct from sleep or full wakefulness. This therapeutic approach, known as hypnotherapy, effectively uses guided suggestion and sensory deprivation to induce a state of catalepsy. During this process, an encephalogram shows specific brain wave changes, indicating a profound shift in consciousness. When performed by trained clinicians, this form of psychotherapy offers significant benefits for pain relief, habit modification, and treating various mental and physical health conditions, proving its value as a modern intervention.
Abstract
Hypnosis is an externally induced alteration in consciousness as a result of suggestion. Hypnotherapy, also called clinical hypnosis, is the use of...
Adverse Effects Associated With High-Dose Ketamine Infusions For Refractory Pain And Psychiatric Conditions.
Current pain and headache reports – June 19, 2025
Summary
Even powerful treatments like Ketamine, when used at high doses for conditions such as Complex Regional Pain Syndrome or Treatment Resistant Depression, require careful consideration. Examining high-dose Ketamine infusions reveals common Adverse Effects. Patients may experience psychiatric symptoms, including Emergence Reactions, agitation, or sleep disturbances, alongside emesis and potentially transient Hepatotoxicity. When properly monitored in a hospital, high-dose Ketamine appears safe, though some effects are dose-dependent.
Abstract
As higher doses of ketamine are being used in numerous medical conditions such as Complex Regional Pain Syndrome (CRPS), it is critical to examine ...
"Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms.
Toxicon : official journal of the International Society on Toxinology – June 07, 2025
Summary
Certain wood-loving magic mushrooms can trigger temporary paralysis in users, affecting 42% of surveyed participants. While Psilocybe mushrooms are known for psychedelic effects, those growing on wood may cause muscle weakness within 4 hours of consumption. This paralysis mainly impacts mobility, with some users experiencing swallowing difficulties. The condition resolves naturally but requires harm reduction awareness.
Abstract
Psilocybin-containing mushrooms have long been used for their psychoactive effects, but emerging evidence suggests that certain lignicolous ("wood-...
Persistent aura without infarction.
Current opinion in neurology – June 01, 2025
Summary
Some migraine auras can persist for days or weeks without causing brain damage, presenting a unique medical challenge. When cortical spreading depression occurs without resolving naturally, it creates continuous visual disturbances and other neurological symptoms. Several medications show promise in treating this condition, including acetazolamide, valproic acid, and zonisamide. Ketamine and furosemide have also demonstrated effectiveness, particularly when combined with cortisone therapy.
Abstract
The scope of this review is to discuss persistent aura without infarction, a rare, highly disabling, yet apparently benign clinical condition, stra...
Neural mass modelling of brain stimulation to Alleviate Schizophrenia biomarkers in brain rhythms.
Computers in biology and medicine – June 01, 2025
Summary
Brain stimulation could hold the key to treating schizophrenia by correcting irregular brain rhythms. Scientists used advanced neural mass models to demonstrate how transcranial direct current stimulation can normalize disrupted thalamocortical circuits. The research showed that targeting specific brain pathways with electrical stimulation effectively reversed EEG abnormalities associated with schizophrenia symptoms, offering promise for personalized treatment approaches.
Abstract
We present a neural mass model (NMM) of the brain thalamo-cortico-thalamic (TCT) network to understand the effectiveness of non-invasive treatment ...
Outpatient Ketamine Prescribing Practices in Psychiatry in the United States: A Nationwide Survey Study.
The Journal of clinical psychiatry – May 26, 2025
Summary
As ketamine emerges as a promising mental health treatment, new data reveals that all surveyed clinics use it for treatment-resistant depression, with 72% even prescribing it to first-time patients. While most clinics offer long-term maintenance treatment, fewer than 30% are run by psychiatric physicians. Over 40% provide at-home options, highlighting both the treatment's growing accessibility and the need for standardized practices.
Abstract
Background: Ketamine is an increasingly popular tool for the treatment of psychiatric disorders. Initially available in controlled studies at acade...
Development and description of a porcine model of combat casualty care for traumatic-hemorrhagic shock research and medical training.
European journal of trauma and emergency surgery : official publication of the European Trauma Society – May 22, 2025
Summary
Combat injuries often combine severe blood loss with physical trauma, yet most medical training relies on oversimplified models. This research evaluated different anesthesia methods in pigs to create a more realistic training platform for combat casualty care. Using a large animal model, researchers compared three anesthesia types while simulating battlefield injuries and hemorrhagic shock. Ketamine-midazolam and isoflurane proved most effective for training purposes, closely mimicking real-world traumatic injury scenarios.
Abstract
Despite the high incidence of death among cases of hemorrhagic shock associated with polytrauma, few animal models are representative of this combi...
Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Journal of Psychedelic Studies – May 16, 2025
Summary
A groundbreaking Aotearoa (New Zealand) project integrates Indigenous Māori healing with psilocybin-assisted therapy to address problematic methamphetamine use. This initiative, drawing on Ethnology, Psychology, and the History of spiritual practices, challenges colonial dynamics in Psychedelics and Drug Studies. It aims to develop a culturally safe approach, respecting Māori wisdom while exploring psilocybin's efficacy. Based in a community with a high Māori population and significant PMU burden, the project seeks to empower a Māori workforce and influence legislation, charting new directions in Religious Studies and collective healing.
Abstract
Abstract Psilocybin, a naturally occurring psychedelic compound found in certain fungi has long been used by Indigenous cultures within ritual and ...
Anesthetic Management of Atypical Toxic Epidermal Necrolysis in a Six-Month-Old Patient Undergoing Burn Surgery: A Case Report.
Cureus – May 01, 2025
Summary
A rare skin condition called toxic epidermal necrolysis (TEN) presented uniquely in a 6-month-old infant, requiring innovative medical care. Doctors successfully managed the challenging case using careful airway procedures and specialized pain control. The team combined ketamine and dexmedetomidine for safe anesthesia, while implementing advanced burn resuscitation techniques. This approach led to successful surgery and recovery.
Abstract
Toxic epidermal necrolysis (TEN) is a rare, life-threatening skin condition that involves widespread skin detachment and mucous membrane damage. We...
Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice.
The Australian and New Zealand journal of psychiatry – April 28, 2025
Summary
Ketamine, once known primarily as an anesthetic, shows promising results in treating severe depression and other psychiatric disorders. New professional practice guidelines from Australia and New Zealand provide clinicians with evidence-based protocols for safe ketamine use in psychiatric treatment. The guidelines emphasize careful patient selection, proper dosing, and monitoring protocols while highlighting ketamine's potential as a rapid-acting intervention for treatment-resistant mental health conditions.
Abstract
Professional practice guidelines for the use of ketamine in psychiatric practice have been developed by the Royal Australian and New Zealand Colleg...
Decreasing Preoperative Anxiety in Patients with Newly Available Multimodal Approaches-A Narrative Review.
Journal of clinical medicine – April 24, 2025
Summary
Anxiety before surgery affects 8 in 10 patients, but innovative approaches are changing this. A combination of medication and therapy shows promising results in reducing patient stress. Anti-anxiety agents provide quick relief, while perioperative care teams now use music, virtual reality, and psychotherapy. Informed consent processes have evolved to be more reassuring and comprehensive.
Abstract
Preoperative anxiety affects approximately 80% of adult patients; thus, identifying patients with excessive anxiety and implementing appropriate in...
Prehospital Ketamine Administration in Benzodiazepine Refractory Status Epilepticus: A Case Series Review.
Prehospital emergency care – April 16, 2025
Summary
When seizures don't respond to standard treatments, ketamine shows remarkable promise, stopping seizures in over 90% of cases. This medication, already used by emergency responders for other conditions, proved highly effective when given to 42 patients whose seizures weren't controlled by conventional drugs. While some patients needed breathing support, the success rate suggests ketamine could be a game-changing option for emergency treatment of persistent seizures.
Abstract
Benzodiazepines are the treatment for seizures in prehospital settings, but fail in up to 40% of cases, leading to benzodiazepine refractory status...
Functional and structural characterization of the human indolethylamine N-methyltransferase through fluorometric, thermal and computational docking analyses.
Biology direct – April 10, 2025
Summary
Scientists have discovered key insights into an enzyme that helps produce DMT, a naturally-occurring psychedelic compound. Using innovative fluorometric techniques, researchers analyzed how the enzyme works with S-adenosylmethionine to transform simple molecules like quinoline. The findings reveal optimal conditions for enzyme function and identify crucial binding sites, advancing our understanding of this biochemical process and its potential therapeutic applications.
Abstract
The "psychedelic renaissance" is sparking growing interest in clinical research, along with a rise in clinical trials. Substances such as 3,4-methy...
Ketamine as part of multi-modal analgesia may reduce opioid requirements following cardiac surgery: a retrospective observational cohort study.
Journal of cardiothoracic surgery – April 03, 2025
Summary
Adding ketamine to pain management after heart surgery can reduce opioid use by nearly 30mg during recovery. This multimodal analgesia approach combines ketamine with standard pain medications, showing promising opioid-sparing effects. Patients receiving ketamine needed significantly fewer pain pills at discharge, with no increase in side effects or complications. This suggests a safer approach to postoperative pain management.
Abstract
Postoperative pain control in cardiac surgery is often managed with opioid medications. Insufficient analgesia can result in complications includin...
Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases.
Journal of child and adolescent psychopharmacology – April 01, 2025
Summary
A single ketamine infusion shows promise as a safe treatment option for teens with severe OCD (obsessive-compulsive disorder). In a groundbreaking trial, five adolescents who hadn't responded to standard treatments received controlled doses. While the immediate reduction in OCD symptoms wasn't sustained long-term, the treatment proved remarkably safe with only mild, temporary side effects.
Abstract
Importance: Selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy are the first-line treatments for pediatric obsessive-...
Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.
Social work – April 01, 2025
Summary
While MDMA shows promise for treating PTSD in adults, social workers express greater confidence in traditional medications for adolescent patients. A survey of 222 social workers revealed they favored selective serotonin reuptake inhibitors over MDMA therapy for treating teen PTSD. However, those with more knowledge about psychedelics showed less stigma and concern, suggesting education could increase acceptance of this emerging treatment.
Abstract
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adoles...
Closed-Loop Systems and Real-Time Neurofeedback in Mindfulness Meditation Research.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
Mindfulness meditation can significantly enhance psychological well-being, but challenges like adherence and session quality often limit its benefits. Innovative approaches using closed-loop systems and real-time neurofeedback show promise in improving engagement with mindfulness practices. For instance, studies utilizing functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have linked mindfulness states to specific brain signals, such as those from the default mode network. By refining these interventions, future applications may boost cognitive and emotional outcomes for participants, potentially increasing their effectiveness by over 30%.
Abstract
Mindfulness meditation has numerous purported benefits for psychological well-being; however, problems such as adherence to mindfulness tasks, qual...
A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.
The Permanente journal – March 14, 2025
Summary
As medicinal psychedelics advance through the FDA pipeline, new treatments could transform mental health care. This analysis examines eight late-phase psychedelic studies and California's parallel legislative efforts to legalize therapeutic use. While state initiatives offer faster access, the FDA's rigorous safety protocols remain crucial for responsible implementation. The review highlights both clinical progress and regulatory challenges in bringing these promising compounds to patients.
Abstract
Psychedelic and empathogenic compounds show promise for a variety of conditions. However, studying these compounds can be highly complex, be very e...
Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study.
Molecular therapy. Methods & clinical development – March 13, 2025
Summary
A promising breakthrough in treating Rett syndrome shows that esketamine, a specialized medication that targets brain receptors, may help improve symptoms in young patients. In this groundbreaking treatment approach, three girls aged 5-10 received weekly intravenous doses, demonstrating positive behavioral changes and increased brain wave activity. The treatment proved both safe and efficient, with only mild side effects, offering new hope for families affected by this rare neurological condition.
Abstract
Rett syndrome (RTT) is a severe neurodevelopmental disorder. N-Methyl-d-aspartate receptor (NMDAR) antagonism has shown therapeutic potential in pr...
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey.
JMIR formative research – March 11, 2025
Summary
Mental health providers overwhelmingly feel confident prescribing medications through telehealth, with 84% reporting high comfort levels. A national survey of 115 providers revealed strong support for digital health prescribing, though comfort decreases when treating out-of-state patients or those never seen in person. While most feel safe prescribing controlled substances remotely, perception varies by provider type and medication class.
Abstract
In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental...
Effect of intraoperative intravenous esketamine on postoperative delirium in older patients undergoing hip fracture surgery: protocol for a randomised, double-blind, placebo-controlled trial.
BMJ open – March 07, 2025
Summary
As hip fracture surgery becomes increasingly common in older adults, doctors are exploring innovative ways to prevent postoperative delirium - a disorienting condition affecting up to 30% of aged patients. A promising clinical trial examines whether esketamine, administered during orthopaedic anaesthesia, can protect elderly patients from developing confusion after hip surgery. The research will track 260 patients, comparing outcomes between those receiving esketamine versus standard care.
Abstract
Postoperative delirium (POD) is a common complication after hip fracture surgery in older patients. Esketamine may be beneficial in alleviating the...
Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.
Disease-a-month : DM – March 01, 2025
Summary
MDMA, known as ecstasy or molly, affects both mind and body by releasing mood-enhancing chemicals. While it creates feelings of euphoria and social connection, this designer drug carries risks. Healthcare providers now focus on harm reduction strategies, as many street versions contain dangerous synthetic cathinones. Understanding both therapeutic potential and overdose risks helps medical teams better treat MDMA-related emergencies.
Abstract
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationall...
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.
JAMA psychiatry – March 01, 2025
Summary
Psychedelic therapy trials face a unique challenge: patients often know whether they've received the actual drug or placebo, potentially skewing results. Recent analysis shows that modifying informed consent forms by carefully limiting information about study design could improve trial accuracy. While this approach shows promise in maintaining scientific integrity, researchers emphasize the need to balance transparency with participant protection and ethical considerations.
Abstract
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination ...
Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy
Journal of Human Services – February 28, 2025
Summary
A majority of human service professionals, educators, and students believe psychedelics show promise for treating psychiatric disorders. A survey of 72 individuals in these fields explored their views. While some expressed uncertainty about potential risks, most agreed that psychedelic use under medical supervision is not unsafe. This positive perspective highlights the importance of developing education and training for future applications.
Abstract
Human service professionals are a vital component of the helping services. Their attitudes toward psychedelics and psychedelic treatments are criti...
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
Clinical Pharmacology & Therapeutics – February 28, 2025
Summary
Paroxetine significantly reduces the unpleasant effects of LSD, a finding critical for psychedelic medicine. In a randomized, double-blind, crossover study, 23 healthy participants receiving paroxetine, versus placebo, experienced less "anxiety," "nausea," and "bad drug effect" from LSD. This pharmacology insight reveals paroxetine increased LSD's concentrations by 1.4-1.5 times, impacting its pharmacokinetics. Such drug studies, exploring chemical synthesis and alkaloids, suggest add-on treatment is well-tolerated, guiding future medicine and potentially dose adjustments, even beyond traditional complementary and alternative medicine approaches.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders...
Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms
OpenAlex – February 27, 2025
Summary
While Western medical models often lack Indigenous wisdom, a groundbreaking Indigenous-led project in Aotearoa is integrating traditional Māori healing with psilocybin-assisted therapy for problematic methamphetamine use. This initiative, part of broader Psychedelics and Drug Studies, challenges conventional Psychology models. Based at Rangiwaho Marae, it pursues three key objectives: exploring psilocybin's efficacy, developing a skilled Māori workforce, and challenging restrictive legislation. This approach charts new directions for culturally resonant, community-driven healing, respecting ancestral knowledge.
Abstract
Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and ...
Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.
Current psychiatry reports – February 01, 2025
Summary
Groundbreaking treatments using MDMA and psychedelics show remarkable promise in treating depression and trauma. While proven effective in adults, these therapies could be particularly transformative for adolescents. Clinical trials demonstrate that MDMA-assisted psychotherapy significantly reduces PTSD symptoms, while psychedelic treatments help overcome resistant depression. These approaches offer new hope for youth mental health.
Abstract
There is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability....
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.
Clinical pharmacokinetics – February 01, 2025
Summary
DMT, a naturally occurring compound being explored for mental health treatment, is one of the fastest-acting psychedelics known, taking effect in minutes. Research shows it's rapidly processed by the body, with effects lasting only 5-20 minutes. The compound spreads widely throughout body tissues and transforms quickly into inactive substances, explaining its brief but intense effects. These findings help explain DMT's unique properties and guide its potential therapeutic use.
Abstract
N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pha...
Prevention of sufentanil-induced cough during induction of general anesthesia by low-dose esketamine.
BMC anesthesiology – January 08, 2025
Summary
During general anesthesia induction, up to 35% of patients experience coughing when given sufentanil, a powerful pain medication. A breakthrough study found that administering low-dose esketamine before sufentanil reduced coughing incidents to just 6% of patients. This simple intervention made anesthesia safer and more comfortable, with no significant side effects or changes in vital signs.
Abstract
Sufentanil is commonly used to induce general anaesthesia due to its rapid onset of action, strong analgesic effect, long-lasting effect, and stabl...